These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 7620214

  • 1. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
    Workman P.
    Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
    [Abstract] [Full Text] [Related]

  • 2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 3. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
    Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D.
    Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
    [Abstract] [Full Text] [Related]

  • 4. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
    Begleiter A, Leith MK, Curphey TJ, Doherty GP.
    Oncol Res; 1997 Sep; 9(6-7):371-82. PubMed ID: 9406243
    [Abstract] [Full Text] [Related]

  • 5. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
    Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH.
    Cancer Res; 2000 Nov 15; 60(22):6384-90. PubMed ID: 11103802
    [Abstract] [Full Text] [Related]

  • 6. DT-diaphorase: a target for new anticancer drugs.
    Danson S, Ward TH, Butler J, Ranson M.
    Cancer Treat Rev; 2004 Aug 15; 30(5):437-49. PubMed ID: 15245776
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Advances in research on DT-diaphorase--catalytic properties, regulation of activity and significance in the detoxication of foreign compounds.
    Horie S.
    Kitasato Arch Exp Med; 1990 Apr 15; 63(1):11-30. PubMed ID: 2125671
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts.
    Halinska A, Belej T, O'Brien PJ.
    Br J Cancer Suppl; 1996 Jul 15; 27():S23-7. PubMed ID: 8763840
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
    Beall HD, Winski SI.
    Front Biosci; 2000 Jul 01; 5():D639-48. PubMed ID: 10877993
    [Abstract] [Full Text] [Related]

  • 12. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.
    Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW.
    Oncol Res; 1994 Jul 01; 6(10-11):493-500. PubMed ID: 7620217
    [Abstract] [Full Text] [Related]

  • 13. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
    Powis G, Gasdaska PY, Gallegos A, Sherrill K, Goodman D.
    Anticancer Res; 1995 Jul 01; 15(4):1141-5. PubMed ID: 7653992
    [Abstract] [Full Text] [Related]

  • 14. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
    Walton MI, Smith PJ, Workman P.
    Cancer Commun; 1991 Jul 01; 3(7):199-206. PubMed ID: 1714284
    [Abstract] [Full Text] [Related]

  • 15. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
    Begleiter A, Leith MK, Curphey TJ.
    Br J Cancer Suppl; 1996 Jul 01; 27():S9-14. PubMed ID: 8763837
    [Abstract] [Full Text] [Related]

  • 16. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
    Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D.
    Cancer Res; 1994 Jun 15; 54(12):3196-201. PubMed ID: 8205540
    [Abstract] [Full Text] [Related]

  • 17. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E, Hendriks HR, Peters GJ.
    Gen Pharmacol; 1996 Apr 15; 27(3):421-9. PubMed ID: 8723519
    [Abstract] [Full Text] [Related]

  • 18. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
    Chen S, Knox R, Lewis AD, Friedlos F, Workman P, Deng PS, Fung M, Ebenstein D, Wu K, Tsai TM.
    Mol Pharmacol; 1995 May 15; 47(5):934-9. PubMed ID: 7746280
    [Abstract] [Full Text] [Related]

  • 19. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
    Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P.
    Mol Pharmacol; 2000 Nov 15; 58(5):1146-55. PubMed ID: 11040064
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.